Prime Medicine, Inc./$PRME
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Ticker
$PRME
Sector
Primary listing
Employees
214
Headquarters
Website
PRME Metrics
BasicAdvanced
$644M
-
-$1.45
-
-
Price and volume
Market cap
$644M
52-week high
$6.94
52-week low
$1.11
Average daily volume
4M
Financial strength
Total debt to equity
196.74
Profitability
EBITDA (TTM)
-196.655
Gross margin (TTM)
-1,808.60%
Net profit margin (TTM)
-3,301.64%
Operating margin (TTM)
-3,412.48%
Revenue per employee (TTM)
$30,000
Management effectiveness
Valuation
Price to revenue (TTM)
87.379
Price to book
8.2
Price to tangible book (TTM)
8.2
Growth
Revenue change (TTM)
647.13%
Earnings per share change (TTM)
-28.16%
3-year earnings per share growth (CAGR)
-45.02%
Bulls say / Bears say
Prime Medicine reported positive Phase 1/2 proof-of-concept results for PM359 in CGD, with rapid engraftment and restored DHR positivity and no serious adverse events—analysts called this 'solid proof-of-concept' for Prime Editing (BioPharma Dive)
The company secured up to $24 million in additional funding from the Cystic Fibrosis Foundation to support its CF program, signaling strong outside validation and reducing short-term funding pressure (Cystic Fibrosis Foundation)
Prime Medicine completed an underwritten public offering in August 2025, raising $144.2 million and extending its cash runway into 2027, highlighting investor confidence in its strategic focus (Prime Medicine)
Prime Medicine's decision to cut about 25% of its workforce and deprioritize its CGD program could reduce R&D capacity and slow progress across its pipeline as the company focuses on fewer programs (BioPharma Dive)
As of March 31, 2025, Prime Medicine held just over $144 million in cash, providing runway only through the first half of 2026—this highlights its high cash burn and suggests more financing will be needed before it achieves key milestones (BioPharma Dive)
Prime Medicine is currently in binding arbitration with Beam Therapeutics over AATD rights, introducing legal risk that could delay or restrict development of an important program (BioPharma Dive)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prime Medicine, Inc. stock?
Prime Medicine, Inc. (PRME) has a market cap of $644M as of November 10, 2025.
What is the P/E ratio for Prime Medicine, Inc. stock?
The price to earnings (P/E) ratio for Prime Medicine, Inc. (PRME) stock is 0 as of November 10, 2025.
Does Prime Medicine, Inc. stock pay dividends?
No, Prime Medicine, Inc. (PRME) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next Prime Medicine, Inc. dividend payment date?
Prime Medicine, Inc. (PRME) stock does not pay dividends to its shareholders.
What is the beta indicator for Prime Medicine, Inc.?
Prime Medicine, Inc. (PRME) does not currently have a Beta indicator.